Clinical Trials
Self-Acupressure Alleviates Symptom Cluster in Breast Cancer Survivors: Phase III Trial
Li et alSupportive Care in Cancer

A phase III randomized controlled trial evaluated the efficacy, safety, and within-trial costs of self-acupressure for managing the fatigue-sleep disturbance-depression symptom cluster (FSDSC) in breast cancer survivors. A total of 108 participants were randomized equally (n = 36 per arm) into true self-acupressure, sham self-acupressure, or usual care groups, with 93 participants completing the study protocol. Assessments were performed at baseline (T0, week 0), immediately following the intervention (T1, week 7), and at extended follow-up (T2, week 19).
The primary endpoint assessed FSDSC at both the composite cluster level (mean of three 0–10 numeric rating scale scores) and individual symptom levels using the Brief Fatigue Inventory (BFI), Pittsburgh Sleep Quality Index (PSQI), and Hospital Anxiety and Depression Scale-Depression subscale (HADS-D). Secondary clinical evaluation assessed quality of life (QoL) via the Functional Assessment of Cancer Therapy-Breast (FACT-B). Statistically significant group-by-time interactions were confirmed across all clinical and QoL metrics. Pairwise comparisons revealed that true self-acupressure produced significantly superior reductions in composite FSDSC scores compared to both sham and usual care cohorts at both T1 and T2 (all p < 0.01).
For individual symptom domains, true self-acupressure led to significantly superior PSQI and HADS-D improvements compared with both sham and usual care at weeks 7 and 19 (all p < 0.05). BFI fatigue scores were significantly lower in the true self-acupressure group compared with usual care at both post-intervention time points (both p < 0.0001); the reduction compared to sham self-acupressure became statistically significant at week 19 (p = 0.0076). FACT-B total scores were significantly higher in the true self-acupressure cohort versus usual care at weeks 7 and 19 (both p < 0.0001), while the difference over sham acupressure was nonsignificant at week 7 (p = 0.069) but reached statistical significance at week 19 (p = 0.0002).
Intervention safety was demonstrated with no adverse events reported throughout the study. Economic resource utilization data showed one participant in the true self-acupressure group incurred ¥931.06 in symptom-related healthcare costs compared to one patient in the usual care group incurring ¥2247.44, alongside a one-time video production cost of ¥2879 for the intervention. Although self-acupressure proved clinically effective and safe for breast cancer survivorship symptom clusters, its long-term cost-effectiveness remains uncertain.
Key Takeaways
- True self-acupressure significantly improved the fatigue-sleep disturbance-depression symptom cluster score compared with both sham acupressure and usual care at week 7 and week 19 (all p < 0.01).
- Compared with sham acupressure, true self-acupressure demonstrated superior sleep quality on the PSQI and depression scores on the HADS-D at both weeks 7 and 19 (all p < 0.05), while significant reductions in fatigue on the BFI emerged by week 19 (p = 0.0076).
- True self-acupressure significantly enhanced quality of life on the FACT-B versus usual care at weeks 7 and 19 (both p < 0.0001) and outperformed sham acupressure by week 19 (p = 0.0002), with zero adverse events reported.
Read the original sourceSupportive Care in Cancer
